drugset / Trial / NCT06022146
A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a prospective, multi-center, open-label, cluster randomized controlled clinical trial conducted in school settings to estimate the non-inferiority effect of 1H3P3 compared with 3HR.
Timeline
- Start
- 2023-09-01
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Isoniazid | Small molecule | 400 mg | — |
| Comparator | Isoniazid | Small molecule | — | — |
| Comparator | Rifampin | Small molecule | — | — |
| Subject | Rifapentine | Small molecule | 450 mg | — |